Parnell Pharmaceuticals Holdings Net Income 2014-2018 | PARNF
Parnell Pharmaceuticals Holdings net income from 2014 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Parnell Pharmaceuticals Holdings Annual Net Income
(Millions of US $) |
| 2021 |
$-1 |
| 2020 |
$-10 |
| 2019 |
$-5 |
| 2018 |
$0 |
| 2017 |
$-18 |
| 2016 |
$-16 |
| 2015 |
$-10 |
| 2014 |
$-13 |
| 2014 |
$0 |
| 2013 |
$-16 |
| 2013 |
$0 |
| 2012 |
$-4 |
Parnell Pharmaceuticals Holdings Quarterly Net Income
(Millions of US $) |
| 2018-06-30 |
|
| 2018-03-31 |
$0 |
| 2017-12-31 |
|
| 2016-12-31 |
$-2 |
| 2016-09-30 |
$-5 |
| 2015-12-31 |
$-6 |
| 2015-09-30 |
$-2 |
| 2015-06-30 |
$-2 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
$0 |
| 2014-09-30 |
$-1 |
| 2014-06-30 |
|
| 2014-03-31 |
$-5 |
| 2013-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell's premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia.
|
